APA

Yokota T., Hatooka S., Ura T., Abe T., Takahari D., Shitara K., Nomura M., Kondo C., Mizota A., Yatabe Y., Shinoda M. & Muro K. (20111122). Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. : Anticancer research.

Chicago

Yokota Tomoya, Hatooka Shunzo, Ura Takashi, Abe Tetsuya, Takahari Daisuke, Shitara Kohei, Nomura Motoo, Kondo Chihiro, Mizota Ayako, Yatabe Yasushi, Shinoda Masayuki and Muro Kei. 20111122. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. : Anticancer research.

Harvard

Yokota T., Hatooka S., Ura T., Abe T., Takahari D., Shitara K., Nomura M., Kondo C., Mizota A., Yatabe Y., Shinoda M. and Muro K. (20111122). Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. : Anticancer research.

MLA

Yokota Tomoya, Hatooka Shunzo, Ura Takashi, Abe Tetsuya, Takahari Daisuke, Shitara Kohei, Nomura Motoo, Kondo Chihiro, Mizota Ayako, Yatabe Yasushi, Shinoda Masayuki and Muro Kei. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. : Anticancer research. 20111122.